Cancer
FDA advisory committee approves the use of Lynparza in pancreatic cancer
December 18, 2019Research and Development AstraZeneca, Cancer, Merck, Pancreatic cancer, lynparza
The FDA’s Oncologic Drugs Advisory Committee (ODAC) has recommended the approval of AstraZeneca and Merck’s Lynparza (olaparib) to treat pancreatic …
FDA approves Pfizer and Astellas Pharma’s prostate cancer drug
December 17, 2019Manufacturing and Production Astellas Pharma, Cancer, FDA, Pfizer, Xtandi, prostate cancer
The FDA has approved Pfizer and Astellas Pharma’s Xtandi (enzalutamide) to treat patients with a type of prostate cancer. The …
Transgene ceases development of failed advanced non-squamous non-small cell lung cancer immunotherapy candidate
December 16, 2019Research and Development, Sales and Marketing Cancer, Transgene, lung cancer, pharma
Cancer immunotherapeutics firm Transgene has confirmed that it is to terminate further development of its TG4010 candidate in the first-line …
Roche’s subcutaneous Perjeta/Herceptin combo proves non-inferior to IV formulation in HER2-positive early breast cancer
December 12, 2019Research and Development Cancer, Herceptin, Perjeta, Roche, breast cancer, pharma
New Phase 3 data from Roche has shown that its subcutaneously-delivered formulation of Perjeta (pertuzumab) and Herceptin (trastuzumab), in combination …
Takeda commits to advancing treatments for rare bleeding disorders and cancer
December 10, 2019Manufacturing and Production, Research and Development ASH 19, Cancer, Takeda, lymphoma, oncology
Takeda presented at the 61st American Society of Hematology (ASH) Annual Meeting, 29 company-sponsored abstracts to highlight its commitment to …
Top Ten most popular articles on Pharmafile.com this week
December 6, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, FDA, NHS, corruption, lung cancer, opiods crisis, opioids
Corruption and bribery feature heavily in the news this week. A recently exposed 1997 email chain shows Dr Richard Sackler, …
NICE authorises Lynparza for NHS use in all BRCA-mutated ovarian cancer cases
December 2, 2019Sales and Marketing Cancer, NHS, NICE, lynparza, ovarian cancer, pharma
NICE has given its recommendation for the routine use on the NHS in England and Wales of AstraZeneca and MSD’s …
FDA gives priority review for AstraZeneca’s Imfinzi
November 29, 2019Medical Communications AstraZeneca, Cancer, FDA, Imfinzi, lung cancer
The FDA has granted a priority review of AstraZeneca’s cancer treatment drug Imfinzi (durvalumab) for treatment of patients with untreated …
Prostate Cancer ‘super responders’ could live for two more years on Keytruda
November 28, 2019Research and Development Cancer, immunotherapy, keytruda, oncology, prostate cancer
Men with advanced prostate cancer, who have exhausted all treatment options, could use the immunotherapy Keytruda (pembrolizumab) to live for …
Roche’s Tecentriq combo outclasses Nexavar in unresectable hepatocellular carcinoma
November 25, 2019Research and Development, Sales and Marketing Cancer, Roche, immunotherapy, pharma, tecentriq
Roche has revealed new Phase 3 data for its immunotherapy drug Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) in the …
Europe approves Keytruda for first-line head and neck squamous cell carcinoma, as a monotherapy or combo
November 20, 2019Research and Development, Sales and Marketing Cancer, keytruda, pharma
MSD’s top-selling immunotherapy Keytruda (pembrolizumab) has secured another approval from the European Commission, this time in the first-line treatment of …
Novartis’ Kisqali approved for NHS Scotland in most common advanced breast cancer
November 12, 2019Manufacturing and Production, Sales and Marketing Cancer, Kisqali, NHS, Novartis, Scotland, breast cancer, pharma
NHS patients in Scotland will soon be able to access Novartis’ CDK4/6 inhibitor Kisqali (ribociclib) after the Scottish Medicines Consortium …
Amgen drops $2.7bn to acquire stake in Chinese biotech in bid to expand in the region
November 1, 2019Medical Communications, Research and Development, Sales and Marketing Amgen, BeiGene, Cancer, China, deal, oncology, pharma
Amgen has signed an agreement with Chinese biotech BeiGene to acquire a 20.5% stake in the latter, in a bid …
Bavencio+Inlyta combo OK’d in Europe for first-line advanced kidney cancer
October 29, 2019Manufacturing and Production, Sales and Marketing Bavencio, Cancer, Kidney cancer, Merck KGaA, Pfizer, inlyta, pharma
Merck KGaA and Pfizer’s joint drug Bavencio (avelumab) has received European approval in combination with Inlyta (axitinib) in the first-line …
AstraZeneca’s Imfinzi triple combo beats chemo in treatment-naive metastatic lung cancer
October 29, 2019Manufacturing and Production, Research and Development AstraZeneca, Cancer, Imfinzi, NSCLC, lung cancer, pharma
AstraZeneca has unveiled positive new Phase 3 data for the combination of Imfinzi (durvalumab) and anti-CTLA4 antibody tremelimumab with chemotherapy …
Latest content
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion
